These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25810134)

  • 1. Efficient molecular subtype classification of high-grade serous ovarian cancer.
    Leong HS; Galletta L; Etemadmoghadam D; George J; ; Köbel M; Ramus SJ; Bowtell D
    J Pathol; 2015 Jul; 236(3):272-7. PubMed ID: 25810134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.
    Park JS; Choi SB; Kim HJ; Cho NH; Kim SW; Kim YT; Nam EJ; Chung JW; Kim DW
    Int J Gynecol Cancer; 2016 Jan; 26(1):104-13. PubMed ID: 26512784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
    Sung CO; Song IH; Sohn I
    Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
    Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
    Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
    Takamatsu S; Hillman RT; Yoshihara K; Baba T; Shimada M; Yoshida H; Kajiyama H; Oda K; Mandai M; Okamoto A; Enomoto T; Matsumura N
    Br J Cancer; 2024 Nov; 131(8):1340-1349. PubMed ID: 39215190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.
    Lin S; Wang C; Zarei S; Bell DA; Kerr SE; Runger GC; Kocher JA
    BMC Genomics; 2018 Nov; 19(1):841. PubMed ID: 30482155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival.
    Kernagis DN; Hall AH; Datto MB
    J Mol Diagn; 2012; 14(3):214-22. PubMed ID: 22490445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
    Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
    J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
    BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Set-Based Integrative Analysis Revealing Two Distinct Functional Regulation Patterns in Four Common Subtypes of Epithelial Ovarian Cancer.
    Chang CM; Chuang CM; Wang ML; Yang YP; Chuang JH; Yang MJ; Yen MS; Chiou SH; Chang CC
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27527159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
    Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
    Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity.
    Bodelon C; Killian JK; Sampson JN; Anderson WF; Matsuno R; Brinton LA; Lissowska J; Anglesio MS; Bowtell DDL; Doherty JA; Ramus SJ; Talhouk A; Sherman ME; Wentzensen N
    Clin Cancer Res; 2019 Oct; 25(19):5937-5946. PubMed ID: 31142506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.